Skip to main content
Top
Published in: Journal of Translational Medicine 1/2010

Open Access 01-12-2010 | Research

Morphologic complexity of epithelial architecture for predicting invasive breast cancer survival

Authors: Mauro Tambasco, Misha Eliasziw, Anthony M Magliocco

Published in: Journal of Translational Medicine | Issue 1/2010

Login to get access

Abstract

Background

Precise criteria for optimal patient selection for adjuvant chemotherapy remain controversial and include subjective components such as tumour morphometry (pathological grade). There is a need to replace subjective criteria with objective measurements to improve risk assessment and therapeutic decisions. We assessed the prognostic value of fractal dimension (an objective measure of morphologic complexity) for invasive ductal carcinoma of the breast.

Methods

We applied fractal analysis to pan-cytokeratin stained tissue microarray (TMA) cores derived from 379 patients. Patients were categorized according to low (<1.56, N = 141), intermediate (1.56-1.75, N = 148), and high (>1.75, N = 90) fractal dimension. Cox proportional-hazards regression was used to assess the relationship between disease-specific and overall survival and fractal dimension, tumour size, grade, nodal status, estrogen receptor status, and HER-2/neu status.

Results

Patients with higher fractal score had significantly lower disease-specific 10-year survival (25.0%, 56.4%, and 69.4% for high, intermediate, and low fractal dimension, respectively, p < 0.001). Overall 10-year survival showed a similar association. Fractal dimension, nodal status, and grade were the only significant (P < 0.05) independent predictors for both disease-specific and overall survival. Among all of the prognosticators, the fractal dimension hazard ratio for disease-specific survival, 2.6 (95% confidence interval (CI) = 1.4,4.8; P = 0.002), was second only to the slightly higher hazard ratio of 3.1 (95% CI = 1.9,5.1; P < 0.001) for nodal status. As for overall survival, fractal dimension had the highest hazard ratio, 2.7 (95% CI = 1.6,4.7); P < 0.001). Split-sample cross-validation analysis suggests these results are generalizable.

Conclusion

Except for nodal status, morphologic complexity of breast epithelium as measured quantitatively by fractal dimension was more strongly and significantly associated with disease-specific and overall survival than standard prognosticators.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lonning PE, Knappskog S, Staalesen V, Chrisanthar R, Lillehaug JR: Breast cancer prognostication and prediction in the postgenomic era. Ann Oncol. 2007, 18: 1293-1306. 10.1093/annonc/mdm013.PubMedCrossRef Lonning PE, Knappskog S, Staalesen V, Chrisanthar R, Lillehaug JR: Breast cancer prognostication and prediction in the postgenomic era. Ann Oncol. 2007, 18: 1293-1306. 10.1093/annonc/mdm013.PubMedCrossRef
2.
go back to reference Cianfrocca M, Gradishar WJ: Controversies in the therapy of early stage breast cancer. Oncologist. 2005, 10: 766-779. 10.1634/theoncologist.10-10-766.PubMedCrossRef Cianfrocca M, Gradishar WJ: Controversies in the therapy of early stage breast cancer. Oncologist. 2005, 10: 766-779. 10.1634/theoncologist.10-10-766.PubMedCrossRef
3.
go back to reference Mori I, Yang Q, Kakudo K: Predictive and prognostic markers for invasive breast cancer. Pathol Int. 2002, 52: 186-194. 10.1046/j.1440-1827.2002.01335.x.PubMedCrossRef Mori I, Yang Q, Kakudo K: Predictive and prognostic markers for invasive breast cancer. Pathol Int. 2002, 52: 186-194. 10.1046/j.1440-1827.2002.01335.x.PubMedCrossRef
4.
go back to reference Cianfrocca M, Goldstein LJ: Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004, 9: 606-616. 10.1634/theoncologist.9-6-606.PubMedCrossRef Cianfrocca M, Goldstein LJ: Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004, 9: 606-616. 10.1634/theoncologist.9-6-606.PubMedCrossRef
5.
go back to reference Mirza AN, Mirza NQ, Vlastos G, Singletary SE: Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg. 2002, 235: 10-26. 10.1097/00000658-200201000-00003.PubMedPubMedCentralCrossRef Mirza AN, Mirza NQ, Vlastos G, Singletary SE: Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg. 2002, 235: 10-26. 10.1097/00000658-200201000-00003.PubMedPubMedCentralCrossRef
6.
go back to reference Elledge RM, McGuire WL: Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. Annu Rev Med. 1993, 44: 201-210. 10.1146/annurev.me.44.020193.001221.PubMedCrossRef Elledge RM, McGuire WL: Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. Annu Rev Med. 1993, 44: 201-210. 10.1146/annurev.me.44.020193.001221.PubMedCrossRef
7.
go back to reference Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998, 352: 930-942. 10.1016/S0140-6736(98)03301-7. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998, 352: 930-942. 10.1016/S0140-6736(98)03301-7.
8.
go back to reference Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998, 351: 1451-1467. 10.1016/S0140-6736(97)11423-4. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998, 351: 1451-1467. 10.1016/S0140-6736(97)11423-4.
9.
go back to reference Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19: 403-410. 10.1111/j.1365-2559.1991.tb00229.x.PubMedCrossRef Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19: 403-410. 10.1111/j.1365-2559.1991.tb00229.x.PubMedCrossRef
10.
go back to reference Henson DE, Ries L, Freedman LS, Carriaga M: Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer. 1991, 68: 2142-2149. 10.1002/1097-0142(19911115)68:10<2142::AID-CNCR2820681010>3.0.CO;2-D.PubMedCrossRef Henson DE, Ries L, Freedman LS, Carriaga M: Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer. 1991, 68: 2142-2149. 10.1002/1097-0142(19911115)68:10<2142::AID-CNCR2820681010>3.0.CO;2-D.PubMedCrossRef
11.
go back to reference Saez RA, McGuire WL, Clark GM: Prognostic factors in breast cancer. Semin Surg Oncol. 1989, 5: 102-110. 10.1002/ssu.2980050206.PubMedCrossRef Saez RA, McGuire WL, Clark GM: Prognostic factors in breast cancer. Semin Surg Oncol. 1989, 5: 102-110. 10.1002/ssu.2980050206.PubMedCrossRef
12.
go back to reference Meyer JS, Alvarez C, Milikowski C, Olson N, Russo I, Russo J: Breast carcinoma malignancy grading by Bloom-Richardson system vs. proliferation index: reproducibility of grade and advantages of proliferation index. Mod Pathol. 2005, 18: 1067-1078. 10.1038/modpathol.3800388.PubMedCrossRef Meyer JS, Alvarez C, Milikowski C, Olson N, Russo I, Russo J: Breast carcinoma malignancy grading by Bloom-Richardson system vs. proliferation index: reproducibility of grade and advantages of proliferation index. Mod Pathol. 2005, 18: 1067-1078. 10.1038/modpathol.3800388.PubMedCrossRef
13.
go back to reference Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G: Histological grading of breast carcinoma: a study of interobserver agreement. Hum Pathol. 1995, 26: 873-879. 10.1016/0046-8177(95)90010-1.PubMedCrossRef Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G: Histological grading of breast carcinoma: a study of interobserver agreement. Hum Pathol. 1995, 26: 873-879. 10.1016/0046-8177(95)90010-1.PubMedCrossRef
14.
go back to reference Chowdhury N, Pai MR, Lobo FD, Kini H, Varghese R: Interobserver variation in breast cancer grading: a statistical modeling approach. Anal Quant Cytol Histol. 2006, 28: 213-218.PubMed Chowdhury N, Pai MR, Lobo FD, Kini H, Varghese R: Interobserver variation in breast cancer grading: a statistical modeling approach. Anal Quant Cytol Histol. 2006, 28: 213-218.PubMed
15.
go back to reference Rizki A, Bissell MJ: Homeostasis in the breast: it takes a village. Cancer Cell. 2004, 6: 1-2. 10.1016/j.ccr.2004.06.019.PubMedCrossRef Rizki A, Bissell MJ: Homeostasis in the breast: it takes a village. Cancer Cell. 2004, 6: 1-2. 10.1016/j.ccr.2004.06.019.PubMedCrossRef
16.
go back to reference Coffey DS: Self-organization, complexity and chaos: the new biology for medicine. Nat Med. 1998, 4: 882-885. 10.1038/nm0898-882.PubMedCrossRef Coffey DS: Self-organization, complexity and chaos: the new biology for medicine. Nat Med. 1998, 4: 882-885. 10.1038/nm0898-882.PubMedCrossRef
17.
18.
go back to reference Tambasco M, Costello BM, Kouznetsov A, Yau A, Magliocco AM: Quantifying the architectural complexity of microscopic images of histology specimens. Micron. 2009, 40: 486-494. 10.1016/j.micron.2008.12.004.PubMedCrossRef Tambasco M, Costello BM, Kouznetsov A, Yau A, Magliocco AM: Quantifying the architectural complexity of microscopic images of histology specimens. Micron. 2009, 40: 486-494. 10.1016/j.micron.2008.12.004.PubMedCrossRef
19.
go back to reference Peitgen H, Jurgens H, Saupe D: Chaos and Fractals: New Frontiers of Science. 2004, New York: Springer-Verlag, 2CrossRef Peitgen H, Jurgens H, Saupe D: Chaos and Fractals: New Frontiers of Science. 2004, New York: Springer-Verlag, 2CrossRef
20.
go back to reference Dixon V, Tambasco M: Effects of image resolution and noise on estimating the fractal dimension of tissue specimens. Anal Quant Cytol Histol. 2010, 32: 269-279.PubMed Dixon V, Tambasco M: Effects of image resolution and noise on estimating the fractal dimension of tissue specimens. Anal Quant Cytol Histol. 2010, 32: 269-279.PubMed
21.
go back to reference Kleinbaum DG, Kupper LL, Muller KE, Nizam A: Applied Regression Analysis and Other Multivariable Methods. 1998, Duxbury Press, 3 Kleinbaum DG, Kupper LL, Muller KE, Nizam A: Applied Regression Analysis and Other Multivariable Methods. 1998, Duxbury Press, 3
22.
go back to reference Tambasco M, Magliocco AM: Relationship between tumor grade and computed architectural complexity in breast cancer specimens. Hum Pathol. 2008, 39: 740-746. 10.1016/j.humpath.2007.10.001.PubMedCrossRef Tambasco M, Magliocco AM: Relationship between tumor grade and computed architectural complexity in breast cancer specimens. Hum Pathol. 2008, 39: 740-746. 10.1016/j.humpath.2007.10.001.PubMedCrossRef
23.
go back to reference Baish JW, Jain KJ: Fractals and cancer. Cancer Res. 2000, 60: 3683-3688.PubMed Baish JW, Jain KJ: Fractals and cancer. Cancer Res. 2000, 60: 3683-3688.PubMed
24.
go back to reference Cross SS: Fractals in pathology. Journal of Pathology. 1997, 182: 1-8. 10.1002/(SICI)1096-9896(199705)182:1<1::AID-PATH808>3.0.CO;2-B.PubMedCrossRef Cross SS: Fractals in pathology. Journal of Pathology. 1997, 182: 1-8. 10.1002/(SICI)1096-9896(199705)182:1<1::AID-PATH808>3.0.CO;2-B.PubMedCrossRef
Metadata
Title
Morphologic complexity of epithelial architecture for predicting invasive breast cancer survival
Authors
Mauro Tambasco
Misha Eliasziw
Anthony M Magliocco
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2010
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-8-140

Other articles of this Issue 1/2010

Journal of Translational Medicine 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.